{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:49:15Z","timestamp":1785836955967,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jtct.2023.06.007","type":"journal-article","created":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T12:50:54Z","timestamp":1686487854000},"page":"579.e1-579.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age &lt;3 Years with Relapsed\/Refractory Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"29","author":[{"given":"David","family":"Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Acker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Clough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Willert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.06.007_bib0001","series-title":"[prescribing information]","year":"2021"},{"key":"10.1016\/j.jtct.2023.06.007_bib0002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.06.007_bib0003","series-title":"Presented at: EHA 2022 Hybrid Meeting","article-title":"Tisagenlecleucel in pediatric and young adult patients (pts) with relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL): final analyses from the ELIANA study","author":"Rives","year":"2022"},{"key":"10.1016\/j.jtct.2023.06.007_bib0004","series-title":"Presented at: EHA 2018","article-title":"An updated analysis of tisagenlecleucel in pediatric\/young adult patients with relapsed\/refractory (r\/r) B-cell acute lymphoblastic leukemia (B-ALL) in a US multicenter clinical trial (ENSIGN)","author":"Maude","year":"2018"},{"key":"10.1016\/j.jtct.2023.06.007_bib0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MPH.0000000000001857","article-title":"Use of CD19-directed CAR T-cell therapy in an infant with refractory acute lymphoblastic leukemia","volume":"43","author":"Breese","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.06.007_bib0006","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2023.06.007_bib0007","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/bloodadvances.2021006393","article-title":"Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia","volume":"6","author":"Moskop","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.06.007_bib0008","series-title":"Presented at: 61st American Society of Hematology Annual Meeting & Exposition","article-title":"Tisagenlecleucel manufacturing feasibility in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","author":"Eldjerou","year":"2019"},{"key":"10.1016\/j.jtct.2023.06.007_bib0009","series-title":"Presented at: 23rd American Society of Gene & Cell Therapy Annual Meeting (virtual)","article-title":"Leukapheresis and tisagenlecleucel manufacturing in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","author":"Eldjerou","year":"2020"},{"key":"10.1016\/j.jtct.2023.06.007_bib0010","series-title":"Presented at: 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (virtual)","article-title":"Feasibility of tisagenlecleucel manufacturing in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","author":"Eldjerou","year":"2020"},{"key":"10.1016\/j.jtct.2023.06.007_bib0011","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2023.06.007_bib0012","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.06.007_bib0013","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2021-144897","article-title":"Optimizing commercial manufacturing of tisagenlecleucel for patients in the US: a 4-year experiential journey","volume":"138","author":"Rodrigues","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.007_bib0014","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.06.007_bib0015","doi-asserted-by":"crossref","first-page":"e28739","DOI":"10.1002\/pbc.28739","article-title":"Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia","volume":"68","author":"Moskop","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.06.007_bib0016","doi-asserted-by":"crossref","first-page":"e28155","DOI":"10.1002\/pbc.28155","article-title":"Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia","volume":"67","author":"Shyr","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtct.2023.06.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221099468","article-title":"Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports)","volume":"13","author":"Poyer","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"15 Suppl","key":"10.1016\/j.jtct.2023.06.007_bib0018","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.06.007_bib0019","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jca.21812","article-title":"Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric\/adolescent acute lymphoblastic leukemia patients","volume":"35","author":"Jarisch","year":"2020","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jtct.2023.06.007_bib0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12185-021-03191-x","article-title":"Optimization of lymphapheresis for manufacturing autologous CAR-T cells","volume":"114","author":"Yamanaka","year":"2021","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2023.06.007_bib0021","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.06.007_bib0022","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.007_bib0023","unstructured":"U.S. Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. August 30, 2017."},{"key":"10.1016\/j.jtct.2023.06.007_bib0024","series-title":"Presented at: 2022 American Society of Pediatric Hematology\/Oncology (ASPHO) Conference","article-title":"Real-world outcomes for pediatric patients aged <3 years with R\/R ALL treated with tisagenlecleucel","author":"Guest","year":"2022"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2023.06.007_bib0025","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1182\/blood-2021-144939","article-title":"Tisagenlecleucel leukapheresis and manufacturing outcomes in patients less than 3 years of age with relapsed\/refractory acute lymphoblastic leukemia","volume":"138","author":"Willert","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.06.007_bib0026","series-title":"Presented at: EHA Virtual Congress 2021","article-title":"Outcomes of children aged under 3 years treated with tisagenlecleucel for B-ALL","author":"Ghorashian","year":"2021"},{"key":"10.1016\/j.jtct.2023.06.007_bib0027","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtct.2023.06.007_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151178","article-title":"Tisagenlecleucel therapy: nursing considerations for the outpatient setting","volume":"37","author":"Cunningham","year":"2021","journal-title":"Semin Oncol Nurs"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723013556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:10:04Z","timestamp":1763003404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723013556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2666636723013556"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.06.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed\/Refractory Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}